PubMed Health⌕ Search

PubMed · 11670627

Monocyclopentadienyl-Titanium Aryloxide Sulfide Complexes.

Abstract

In this report we extend titanium-sulfide chemistry, describing the syntheses, structures, and chemistry of monocyclopentadienyl-titanium aryloxide sulfide complexes. Reduction of Cp'Ti(OC(6)H(3)-2,6-i-Pr(2))Cl(2) (Cp' = Cp (1), Cp (3)) with n-BuLi affords the Ti(III) compounds [CpTi(OC(6)H(3)-2,6-i-Pr(2))(&mgr;-Cl)](2) (2) and [CpTi(OC(6)H(3)-2,6-i-Pr(2))(&mgr;-Cl)](2) (4). Compound 2 is oxidized by moisture, giving [CpTi(OC(6)H(3)-2,6-i-Pr(2))Cl](2)(&mgr;-O) (5). Oxidation of 4 by sulfur led to a mixture of uncharacterized products; however, reaction of 3 with 2 equiv of n-BuLi followed by subsequent addition of sulfur afforded a new diamagnetic species, CpTi(OC(6)H(3)-2,6-i-Pr(2))S(5) (6). Oxidation of 2 by S(8) yields [CpTi(OC(6)H(3)-2,6-i-Pr(2))](2)(&mgr;-S)(&mgr;-S(2)) (7). Reaction of the known sulfide-bridged dimer [CpTi(OC(6)H(3)-2,6-i-Pr(2))(&mgr;-S)](2) (8) with sulfur provides an alternative route to 7. The conversion of 7 to 8 is reversible as reaction of 7 with PPh(3) yields SPPh(3) and 8 quantitatively. Reaction of 1 with Li(2)S proceeds cleanly to give 8. Reduction of CpTi(OC(6)H(3)-2,6-i-Pr(2))(SPh)Cl (9) with n-BuLi affords the diamagnetic product [CpTi(OC(6)H(3)-2,6-i-Pr(2))(&mgr;-SPh)](2) (10), which reacts with phenylpyridine to generate the paramagnetic species CpTi(OC(6)H(3)-2,6-i-Pr(2))(SPh)(NC(5)H(4)Ph) (11). Attempts to isolate a monosulfide-bridged complex are described. Isolation of a monosulfide-bridged species, [CpTi(OC(6)H(3)-2,6-i-Pr(2))(2)](2)(&mgr;-S) (14), is achieved via reaction of [CpTi(OC(6)H(3)-2,6-i-Pr(2))(2)Cl (13) with Li(2)S. Structural data for 2, 4-7, 10, and 14 are reported. Comparisons are made with the related titanocene-sulfide systems, and the implications are considered.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andrea V. Firth, Douglas W. Stephan. 1998-09-07. Monocyclopentadienyl-Titanium Aryloxide Sulfide Complexes.. https://doi.org/10.1021/ic9800839

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗